Supplier News Breaks Archives
Dr. Reddy's ships three new generics in U.S.
June 6th, 2011
HYDERABAD, India – Dr. Reddy's Laboratories has released generic versions of medications for treating Alzheimer's disease, depression and breast cancer in the United States.
The India-based pharmaceutical maker said Monday that it has rolled out donepezil hydrochloride tablets in 5-mg and 10-mg strengths), available in 30-, 90- and 500-count bottles.
According to the company, the product is a bioequivalent generic version of Eisai's Aricept tablets, which are used to treat dementia stemming from Alzheimer's disease.
Dr. Reddy's also has shipped venlafaxine hydrochloride extended-release capsules in dosages of 37.5 mg, 75 mg and 150 mg strengths. Also available in available in 30-, 90- and 500-count bottles, the medication is a bioequivalent generic version of Wyeth's Effexor XR extended-release capsules for treating major depressive disorder, anxiety and panic disorder.
In addition, Dr. Reddy's has launched letrozole tablets 2.5 mg in 30-count bottles. The company said the product is a bioequivalent generic of Novartis' Femara, a treatment for breast cancer in postmenopausal women.
According to IMS Health data cited by Dr. Reddy's, Aricept brand and donepezil hydrochloride generic tablets had combined U.S. sales of about $2.3 billion for the 12 months ended March 31. Also during that time span, Effexor XR brand and venlafaxine extended-release generic capsules had total U.S. sales of $2.3 billion, and Femara brand tablets had U.S. sales of $702 million.
The Food and Drug Administration approved Dr. Reddy's abbreviated new drug applications (ANDAs) for donepezil hydrochloride tablets and venlafaxine hydrochloride extended-release capsules in May, while the company's ANDA for letrozole tablets was approved last week.